HK Stock Market Move | In early trading, CANSINOBIO (06185) rose by over 6%, launching Phase I clinical trials of a vaccine to prevent acute lower respiratory tract infections and completing the enrollment of the first trial participant.

CANSINOBIO (06185) rose more than 6% in early trading, rising 5.66% to HK$29.7 as of the publication time, with a turnover of HK$24.03 million. In terms of news, CANSINOBIO announced that its "freeze-dried type b influenza bacillus binding vaccine" (Hib vaccine) has officially started Phase I clinical trials recently, and the first subject has been enrolled. It is reported that influenza bacillus is a gram-negative bacillus and one of the main pathogens of acute lower respiratory tract infections in children. The vaccine is expected to induce humoral immunity against Hib after vaccination, providing protection to the vaccinated individuals. In addition, CANSINOBIO recently released its performance. The operating income for the first three quarters was RMB 567 million, an increase of 222.88% year-on-year, with a loss of RMB 222 million. Looking at the third quarter alone, the operating income was RMB 264 million, a year-on-year increase of 76.09%, and net profit was RMB 2.964 million, turning a loss into a profit year-on-year. Haitong pointed out that excluding the estimated impact of returns of COVID-19 vaccines on last year's performance, the operating income for the first three quarters increased by 36.85% year-on-year, mainly due to the rapid growth of revenue from meningococcal vaccines. The company continues to promote and introduce meningococcal vaccine products into the market, with sales revenue of RMB 516 million for the first three quarters of 2024, a year-on-year increase of 39.07%.